Annexe 1 : liste des médicaments remboursés dans le cadre de cette convention

|  |  |
| --- | --- |
| Drug | retained in the convention  as of 01.01.2024 |
| alectinib | yes |
| Alemtuzumab | yes |
| aprepitant | yes |
| Arsene trioxide | yes |
| Atovaquone+proguanil | yes |
| Azacitidine | yes |
| Baricitinib | yes |
| Bendamustine | yes |
| Bevacizumab | yes |
| Blinatumomab | yes |
| Brentixumab vedotine | yes |
| Cabozantinib | yes |
| Cidofovir | yes |
| CMV-Immunoglobulins | yes |
| Cladribine | yes |
| Clofarabine | yes |
| Crizotinib | yes |
| Dabrafenib | yes |
| Denosumab | yes |
| doxorubicin liposomal | yes |
| Erlotinib | yes |
| Everolimus | yes |
| Foscarnet | yes |
| Gemtuzumab ozogamicin | yes |
| *Horse-ATG* | *yes* |
| Human Ig anti CMV | yes |
| Imatinib | yes |
| Infliximab | yes |
| Inotuzumab ozogamicine | yes |
| Interferon alpha | yes |
| Interferon gamma | yes |
| Ipilimumab | yes |
| Lenalidomide | yes |
| Lenvantinib | yes |
| Lorlatinib | yes |
| Lutetium-dotatate | yes |
| Lutetium-octreotate | yes |
| Mitotane | yes |
| Nivolumab | yes |
| palbociclib | yes |
| pazopanib | yes |
| Ponatinib | yes |
| Posaconazole | yes |
| Regorafenib | yes |
| Rivaroxaban | yes |
| Ruxolitinib | yes |
| Sorafenib | yes |
| Thiotepa | yes |
| tocilizumab | yes |
| Trametinib | yes |
| Valganciclovir | yes |
| Venetoclax | yes |
| Vinorelbine | yes |
| zoledroninezuur | yes |